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AbstrAct
The aim of this study was to elucidate the molecular signature of Alzheimer’s 
disease-associated amyloid pathology. 
We used the double APPswe/PS1ΔE9 mouse, a widely used model of cerebral 
amyloidosis, to compare changes in proteome, including global phosphorylation 
and sialylated N-linked glycosylation patterns, pathway-focused transcriptome and 
neurological disease-associated miRNAome with age-matched controls in neocortex, 
hippocampus, olfactory bulb and brainstem. We report that signalling pathways related 
to synaptic functions associated with dendritic spine morphology, neurite outgrowth, 
long-term potentiation, CREB signalling and cytoskeletal dynamics were altered in 12 
month old APPswe/PS1ΔE9 mice, particularly in the neocortex and olfactory bulb. This 
was associated with cerebral amyloidosis as well as formation of argyrophilic tangle-
like structures and microglial clustering in all brain regions, except for brainstem. 
These responses may be epigenetically modulated by the interaction with a number 
of miRNAs regulating spine restructuring, Aβ expression and neuroinflammation. 
We suggest that these changes could be associated with development of cognitive 
dysfunction in early disease states in patients with Alzheimer's disease. 
IntroductIon
Alzheimer's disease (AD) is the leading cause 
of dementia affecting more than 35 million people 
worldwide. Thus, it is crucial to obtain a better 
understanding of the molecular mechanisms underlying 
the neuropathology of AD to identify means to treat this 
disease. 
Studies of human post-mortem brains and AD 
models indicate that synapses are affected at the earliest 
stages of neurodegenerative processes [1]. Importantly, 
AD is characterized by the accumulation of amyloid 
β-peptide (Aβ) in extracellular plaques and intracellular 
neurofibrillary tangles (NFTs), composed of hyper-
phosphorylated microtubule-associated tau protein 
(Mapt), contributing to synaptic degeneration [2]. AD is 
attendant with a number of signs and symptoms including 
abnormalities in cognition, behaviour, olfaction, sleep 
wake cycle and autonomic dysfunction. These functions 
are subserved by a number of brain regions including 
neocortex, hippocampal formation, olfactory system 
and brainstem structures, playing a role in AD pathology 
[3] [4]. The development of Aß and tau pathology 
is predominantly observed in brain areas associated 
with cognition and memory, such as the neocortex and 
hippocampus [5], while several other regions, including 
the brainstem and olfactory bulb, seem to be relatively 
less affected and even understudied [5]. However, these 
brain regions are intertwined via the neocortex as well 
as hippocampal formation and contribute in that way to 
learning and cognition functions. 
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Generally, synaptic activity is one of the most 
important factors that regulate Aβ levels [6] and involves 
signalling mechanisms that shape signalling pathways 
of long-term potentiation (LTP) and –depression (LTD); 
modulation of these have been summarized as synaptic 
plasticity. While LTP is, in part, due to activation of protein 
kinases, such as calmodulin-kinases (Camk´s), protein 
kinases-A (PKA`s) and -C (PKC`s), phosphorylating 
downstream target proteins, LTD arises from activation 
of calcium-dependent phosphatases such as types 1 (PP1) 
and 2 (PP2) dephosphorylating proteins [7]. Consequently, 
protein phosphorylation and -dephosphorylation are crucial 
events in regulating synaptic plasticity. Moreover, there is 
increasing evidence that N-linked glycosylation of proteins 
can also influence neural cell adhesion, axonal targeting 
and neuronal transmission (neurotransmitter release, 
-reception and -uptake) that also significantly contributes 
to pathogenesis of AD [8]. An abnormal glycosylation 
pattern can also influence chronic neuroinflammation [9] 
that is a hallmark in AD. Neuroinflammatory signalling 
can, in turn, be modulated by microRNA´s (miRNA´s) in 
AD [10]. A subset of miRNA´s regulating both neuronal 
and immune processes (neurimmiRs) appear to be 
appropriate diagnostic biomarkers and therapeutic targets 
for neurodegenerative disorders, AD in particular [11]. 
Neuronal signalling pathways that modulate synaptic 
plasticity are multifactorial and include regulatory 
mechanisms involving expression modulation of mRNA, 
miRNA, protein and post-translational modification 
(PTM) of protein. Consequently, a simultaneous cross-
molecular level investigation in multiple brain regions will 
further our understanding aboutthe neuropathology of AD. 
Recently, we showed that the widely used APPswe/
PS1
ΔE9 
(APP/PS1) double transgenic mouse model of 
AD, like patients with AD, show an age-dependent 
sigmoidal increase in cortical Aβ plaque load and a 
chronic neuroinflammatory reaction becoming prominent 
around 12 months of age [12], at a time point when the 
transgenic mouse shows cognitive and behavioural deficits 
[13]. We therefore used this time point for our integrated 
-omics approach to gain more insight into the molecular 
neuropathology of AD in several brain regions to study 
signalling pathways that regulate synaptic plasticity. These 
APPswe/PS1ΔE9 mice were originally made by co-injecting 
two vectors encoding mutant APP (K670N/M671L) and 
mutant PSEN1 (PSEN1ΔE9). These mice begin to develop 
Aβ depositis by 6 months of age, with abundant plaques 
in the neocortex and hippocampus by 12 months and the 
Aβ load increases up till 18 months of age whereafter it 
plateaus [12]. Formation of NFTs is not typical in these 
transgenic mice.
In the present work, we show that the olfactory bulb, 
neocortex, brainstem and hippocampus have a distinctly 
different molecular signature on the synaptic plasticity-
mediated signalling pathways in male APPswe/PS1ΔE9 mice 
at an age of 12 months compared to the age-matched 
controls. The hippocampus seems to be less affected in 
our analysis. Stathmin-mediated microtubuli processing 
and the formation of argyrophilic tangle-like structures as 
well as CREB-mediated synaptic signalling represent the 
major changes observed, particularly in the neocortex and 
olfactory bulb. 
results
the APP/Ps1 mutation leads to changes in 
cytoskeletal proteins associated to synapses
The protein quantification showed a substantial 
increase in the number of deregulated unmodified proteins 
in the olfactory bulb (100 proteins) whereas only a few 
proteins were affected by the APP/PS1 mutation in the 
hippocampus (6 proteins), brainstem (12 proteins) and 
neocortex (4 proteins) (Figure 2A). There was no single 
altered protein overlapping between these different 
brain regions. Phospho- and glyco-proteomics revealed 
a similar picture, where the olfactory bulb showed most 
changes in PTMs (127 proteins) compared to the lower 
number in the hippocampus (39 proteins), brainstem (115 
proteins) and neocortex (53 proteins) (Figure 2B). This 
is based on the number of phosphorylated / formerly 
sialylated N-linked glycosylated peptides found to be 
changed in the olfactory bulb (203), hippocampus (52), 
brainstem (199) and neocortex (72) (Figure 2C). A PCA 
analysis of all quantifiable peptides depicts this context 
(Figure 2F and 2G). There was a distinct grouping of 
the wild-type and APP/PS1-mutated tri-replicates in 
each brain region, respectively, whereas the greatest 
distance, meaning biological difference, was noted in the 
olfactory bulb (Figure 2F and 2G). Using information 
from PhosphoSitePlus database related to AD, we noted 
that Mapt-Ser506, Stmn1-Ser25 and Stmn1-Ser38, that 
are altered in the olfactory bulb of our study, are known 
phosphosites in AD. However, we found also a number of 
new sites related to phosphorylation in these proteins and 
others (SI Tables S2-S5). The complete list of deregulated 
proteins and formerly sialylated N-linked-glycosylated 
as well as phosphorylated proteins with corresponding 
peptide sequences and PANTHER protein class annotation 
can be found in Supplementary Information (SI Tables S1 
– S5).
Noteworthy, protein class analysis revealed that a 
number of proteins function within synaptic cytoskeletal 
structures. Interestingly, more than 30% of all deregulated 
phospho- and glyco-proteins per brain region were 
involved in signalling pathways related to cytoskeleton-
based synaptic plasticity (Figure 2E) compared to the 
much lower percentage found in the global proteomics 
approach to quantify unmodified peptides/proteins 
(neocortex: ~25%, olfactory bulb/brainstem: < 10% 
Oncotarget33629www.impactjournals.com/oncotarget
and hippocampus: 0 %) (Figure 2D). Five phospho-/
glyco-proteins overlapped among the four brain regions 
consisting of the microtubuli-associated proteins Mapt, 
Map2, Map1b, Map1a and Sgip1 (Figure 2B). GO term 
analysis revealed that the majority of deregulated proteins 
on the global proteome and PTMome were associated with 
the cellular component of “cell projection part”, “neuron 
part” and “synapse” that regulate biological processes 
of “cytoskeleton organization”, “neuron projection 
development” and “axon development” (SI Figure S1).   
cytoskeletal, synaptic and neuroprotective 
signalling pathways are affected in transgenic 
mice
To obtain information about the APP/PS1-induced 
signalling pathways, we performed a bioinformatics 
analysis of all deregulated proteins (unmodified, 
phosphorylated and formerly sialylated N-linked 
glycosylated proteins) using IPA software. In spite of 
the relatively low number of shared deregulated proteins 
and modified proteins among the four brain regions, 
the pathways altered by APP/PS1 mutation showed a 
considerable overlap (Figure 3A). The signalling pathways 
Figure 1: Sample processing workflow for miRNA, mRNA and proteome quantification. Panel A shows the complete 
workflow. Panel B highlights the total number of proteins, post-translational modified phospho-/glyoc-peptides and proteins. HILIC, 
hydrophilic interaction chromatography; LC-MS/MS, liquid chromatography-tandem mass spectrometry.
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were associated with cytoskeleton (stathmin1 signalling, 
amyloid processing) and synaptic neuromodulation/-
transmission (14-3-3-mediated signalling, CREB 
signalling, protein kinase A signalling, synaptic long-term 
potentiation) (Figure 2A). Noteworthy, these signalling 
pathways were mainly affected in the olfactory bulb, 
neocortex and brainstem but not in the hippocampus 
(Figure 3A). IPA analysis of diseases and biological 
functions especially addresses neurodegeneration, 
axonogenesis, migration and LTP that are associated 
with synaptic structures as well as apoptosis in the 
neocortex, brainstem and olfactory bulb (Figure 3B-3D). 
No significant changes were noted in the hippocampus 
regarding these classes. 
The analysis of upstream regulators by IPA 
suggested an inhibition of adenosine receptor A2a 
(Adora2a) signalling and MAP kinase-interacting serine/
threonine-protein kinase 1 (Mknk1) in the olfactory bulb 
as well as a predicted inhibition of Mapt in the neocortex 
(Figure 3E and 3F). Significant changes of upstream 
regulators were not observed in hippocampus and 
brainstem. 
Validation of signalling pathways reveal major 
changes in neuronal receptors, neurotrophic 
factors, creb-mediated signalling axis, 
stathmin1 and 14-3-3 proteins
To validate the observed deregulation of signalling 
pathways, biological functions and upstream regulator 
factors, we quantified the expression of 84 mRNA 
transcripts of genes that are associated with synaptic 
plasticity in neurons. We also performed ELISA, 
immunoblotting and immunohistochemistry of key 
proteins / metabolites involved in associated pathways to 
confirm their status of deregulation.
Synaptic alterations were evaluated by mRNA 
transcript quantification of key glutamatergic neuronal 
receptors and neurotrophic factors that were changed in 
varying extent in all brain regions. Details can be found 
in the Supplementary Information section (SI Table 
S6). The glutamate receptors in the neocortex (Grm8), 
olfactory bulb (Grin1, Grm7) and the glutamate receptor-
interacting protein 1 (Grip1) were elevated whereas they 
were not changed in the hippocampus. The insulin-like 
growth factor 1 (Igf1) was increased in the neocortex 
as well in hippocampus, whereas neurotrophin 5 (Ntf5) 
and neuronal pentraxin 2 (Nptx2) as well as serum 
response factor (Srf) were decreased in the neocortex 
and hippocampus, respectively. Important modulators of 
synaptic transmission such as the calmodulin-dependent 
kinase Camk2g (hippocampus) and the transcription 
factors Crem (brainstem) and Nfkb1 (neocortex) were also 
elevated.
As CREB signalling was indicated to be changed 
by the APP/PS1 mutation (Figure 3A), we quantified 
total CREB and p-CREB (Ser133) levels using ELISA. 
We noted significantly reduced expression of p-CREB 
(Ser133) levels compared to total CREB levels (p-CREB 
(Ser133) / total CREB) in the neocortex and olfactory bulb 
(Figure 4A and 4D). However, there was no alteration in 
total CREB and total Creb mRNA transcript expression in 
any brain region (Figure 4A-4D). This is consistent with 
data from IPA signalling pathway analysis regarding CREB 
signalling in the olfactory bulb and neocortex (Figure 
3A) and Adora2a signalling inhibition in the olfactory 
bulb (Figure 3F). The associated signalling pathways 
of Adora2a have CREB as a common downstream 
transcription factor target as revealed by IPA. Next, we 
studied the pathway nodes and key modulators upstream 
of CREB in the APP/PS1 brains. We found a significant 
reduction in cAMP levels only in the brainstem (Figure 
4B) and an increase in Erk1/2 (MAPK) phosphorylation 
(p-Erk1/2 / Erk1/2) in the neocortex and brainstem 
(Figure 4E). The activity of PKA and PKC signalling was 
evaluated by phospho-motif immunoblotting. We noted a 
global increase in phosphorylated proteins with PKA and 
PKC motif in the neocortex and brainstem, respectively 
(Figure 5A, 5B and 5D). 
To validate stahmin1 signalling and 14-3-3-mediated 
signalling obtained from IPA analysis (Figure 3A), we 
performed ELISA and immunoblotting. The results 
suggested an increase in 14-3-3 activity in the olfactory 
bulb (Figure 5C and 5D) as noted by studying the global 
phospho-protein levels with phospho-14-3-3 motif. 
Interestingly, 14-3-3-mediated signalling was not changed 
in any brain region by quantification of Ywhaq (14-3-3 
protein theta) but the protein expression of Ywhaz (14-
3-3 protein zeta/delta) as well as Ywhae (14-3-3 protein 
epsilon) were downregulated in the olfactory bulb 
whereas their phosphorylation status was increased. We 
also noted a decreased phosphorylation of Ywhag (14-
3-3 protein gamma) in the brainstem. Moreover, we 
observed a reduction in p-stathmin1 (Ser16) levels in the 
neocortex (Figure 4A) whereas there was both an increase 
in p-stathmin1 (Ser16) and a decrease in stathmin1 levels 
in the olfactory bulb (Figure 4D) reflecting the pathway 
changes of stathmin1 signalling seen in neocortex and 
olfactory bulb by IPA (Figure 3A). This is congruent with 
our proteomics data (neocortex: unchanged Stmn1 levels, 
decreased phosphorylation of Stmn1 based on single 
phospho-peptide (Ser16); olfactory bulb: reduced Stmn1 
levels, increased phosphorylation of Stmn1 based on 3 
phospho-peptides (Ser16, Ser25; Ser16; Ser38) (SI Table 
S1, S2, S5). We also observed an increase of hippocampal 
p-Stathmin1 (increase in a single phospho-peptide on 
Ser63) whereas no changes in phospho-Stathmin1 were 
noted in the brainstem. As IPA analysis of diseases and 
biological functions address neurodegeneration and 
apoptosis in the neocortex, brainstem and olfactory 
bulb (Figure 3B –D), we quantified levels of activated 
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Caspase-3, which was only significantly elevated in the 
brainstem (Figure 4B).
Argyrophilic tangle-like structures occur in 12 
month old APP/Ps1 mice
As stathmins interact with microtubules and 
microtubule-associated protein tau (Mapt) [14], we 
used a modified Gallyas method enabling us to visualise 
argyrophilic structures, including NFTs in AD. NFTs 
derive, in part, from cytoskeletal proteins with the 
phosphorylated tau protein being particularly abundant in 
these structures [15]. Argyrophilic lesions were observed 
in the neocortex of transgenic mice as well asolfactory 
bulb and hippocampus, respectively (Figure 6A). Gallyas-
positive argyrophilic structures were frequently detected 
within a dark brown background. The argyrophilic 
structures present in the APP/PS1 mouse brain resembled 
those in post-mortem preparations from the neocortex of 
an AD patient (Figure 6D). However, argyrophilic neuropil 
threads were observed in human post-mortem brain but 
Figure 2: Mass spectrometry-based proteomics of proteins and post-translational modified proteins. Venn diagram 
showing the number of all and shared deregulated unmodified proteins A. and phosphorylated / N-linked glycosylated proteins B. as well as 
peptides C. in the hippocampus, olfactory bulb, neocortex and brainstem in 12 month old APP/PS1 male mice compared against age-matched 
controls; n = 3. The number above each brain region shows the total number of changed hits per brain region. The number of deregulated 
hits from the global proteomics experiments in the hippocampus, neocortex, olfactory bulb and brainstem belonging to the protein class 
‘‘cytoskeleton-based synaptic plasticity’’ (Table S1 - S5) compared to all deregulated hits in the respective brain region is shown in panel 
D. and E. Figure D shows that 0 (0%), 1 (25%), 10 (10%)  and 1 (8.3%) unmodified proteins from all unmodified deregulated proteins of 
hippocampus, neocortex, olfactory bulb and brainstem, respectively, are grouped into this class. Figure E shows that 16 (41%), 16 (30.2%), 
36 (28.1%) and 42 (36.2%) phosphorylated/N-linked glycosylated proteins from all phosphorylated/N-linked glycosylated deregulated 
proteins of hippocampus, neocortex, olfactory bulb and brainstem, respectively, are grouped into this class. The class “cytoskeleton-based 
synaptic plasticity” is based on the protein affiliations into sub-protein classes obtained from the PANTHER software (PANTHER protein 
class) as shown in Table S1 - S5 (PANTHER protein classes are highlighted in yellow) involving cytoskeleton-associated processes of 
tubulin and actin. Principal component analysis (PCA) is shown in panel F. and G. OB, olfactory bulb; H, hippocampus; C, cortex; BS, 
brainstem; AD, Alzheimer's; WT, wild-type. 
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not in APP/PS1 mice (Figure 6D). No argyrophilic lesions 
were observed in the brainstem of transgenic animals or 
the brain of wild-type controls (Figure 6A). Data from 
phospho-proteomics experiments indicated an altered 
phosphorylation pattern of Mapt in the olfactory bulb 
(7 phospho-peptides), neocortex (1 phospho-peptide), 
brainstem (2 phospho-peptides) and hippocampus (3 
phospho-peptides) (SI Table S2 to S5). 
Since the APP/PS1 mouse is essentially a model for 
cerebral amyloidosis, we also visualized Aβ plaques by 
the 6E10 antibody raised against human Aβ.  Variable-
sized Aβ plaques were observed throughout the neocortex 
Figure 3: evaluation of affected signalling pathway, biological and disease function as well as upstream regulator 
analysis. Altered signalling pathways in the hippocampus (H), olfactory bulb (OB), neocortex C and brainstem (BS) using the Ingenuity 
Pathway Analysis software are shown in panel A. High color intensity represents high significance (p value) of the pathway. All colored 
boxes have a p value of ≤0.05; white boxes have a p value of ≥0.05 and are not significantly changed; n = 3 in each brain region. Significant 
biological / disease functions B. - D. and upstream regulator analysis E. - F. from IPA software (z-score > 2.0: predicted significant 
activation of node; z-score < 2.0: predicted significant inhibition of node) were grouped and visualized for neocortex, olfactory bulb and 
brainstem. There was no significant change in case of hippocampus. Black circle, non-modified protein; no circle, phosphorylated/ N-linked 
glycosylated protein; protein hit in red, up-regulated expression; protein hit in green, down-regulated expression; orange node of biological 
function: predicted activation; blue node of biological function: predicted inhibition.Adora2a, adenosine receptor A2a; Mknk1; MAP 
kinase-interacting serine/threonine-protein kinase 1; Mapt; microtubuli-associated protein tau.
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of transgenic mice (Figure 6B). 6E10 immuno-positive 
plaques were also present in the hippocampus of APP/
PS1 mice (Figure 6B). Aβ plaques were further noted in 
the olfactory bulb, but not in the APP/PS1 brainstem or 
wild-type mice (Figure 6B). Proteomics data indicated an 
increase in Amyloid beta A4 protein (App) in neocortex, 
hippocampus and brainstem but not in the olfactory bulb 
as the fold-change was only 0.93 and is not reaching our 
set proteomics analysis parameters (SI Table S1). The 
identified App peptides correspond to both human and 
murine peptide sequences. 
APP/Ps1 leads to changes in mirnA expression 
and modulation of neuroinflammatory processes
Epigenetic regulation via miRNAs is rapidly 
recognized as central regulators of gene and protein 
expression in the postnatal mammalian brain. Thus, 
we studied the profile of 84 miRNAs associated with 
neurological development and neurological cognitive 
diseases such as autistic disorders, schizophrenia, AD 
and Huntington´s disease. Details can be found in the 
Supplementary Information section (SI Table S7). 
We found in total 8, 7, 11 and 1 miRNAs significantly 
regulated in the hippocampus, olfactory bulb, neocortex 
and brainstem, respectively (Figure 7A and 7B). Only 
2 deregulated miRNAs overlapped between the brain 
regions consisting of the miR-128-3p (down-regulated 
in hippocampus and olfactory bulb) and let-7i-5p (up-
regulated in neocortex and olfactory bulb) (Figure 7A and 
7B). 
Figure 7C shows that a number of miRNAs are 
associated to signalling pathways involved in synaptic 
plasticity (glutamatergic synapse, axon guidance, long-
term potentiation, MAPK signalling pathway, regulation 
of actin cytoskeleton) as well as inflammatory modulation 
Figure 4: elIsA and immunoblotting of targets involved in creb signalling, lipid peroxidation and microtubule-
processing in hippocampus, neocortex, olfactory bulb and brainstem. Data from ELISA of total CREB, phospho-CREB(Ser133), 
stathmin1, phospho-stathmin1(Ser16), TNFα, caspase3 and cAMP are depicted in panel A (neocortex), B (brainstem), C (hippocampus) 
and D (olfactory bulb). Panel E and F show the data from Erk1/2, p-Erk1/2 and MDA quantification using immunoblotting. The columns 
represent the fold-changes with standard errors of the mean (SEM); n = 3; *p < 0.05; **p < 0.01; ***p < 0.001 (unpaired Student´s t-test). 
Normalization was performed against endogenous GAPDH for all ELISA targets, Erk1/2 and p-Erk1/2; MDA content was normalized 
against total lane intensity via Ponceau S staining. MDA, malondialdehyde; WT, wild-type.
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(insulin/insulin-like growth factor signalling, neurotrophin 
signalling, cytokine-cytokine receptor interaction). The 
involvement of inflammatory processes in hippocampus, 
olfactory bulb and neocortex but not brainstem (Figure 
7C) is in good agreement with the observation of clusters 
of microglia stained with anti-iba1 antibody in the 
hippocampus, olfactory bulb and neocortex, whereas 
no microglial clusters were noted in the brainstem of 
transgenic mice (Figure 6C). Anti-iba1 stained visibly 
more intensely in APP/PS1 brain sections compared 
with control tissue (Figure 6C). Contrastingly, we noted 
only an increased TNFα level in the brainstem (Figure 
4B) that was not associated to persistent oxidative stress 
(quantification of lipid peroxidation by total MDA-
modified protein content) (Figure 4F).
Integrative network analysis of altered proteome, 
PtMome as well as pathway-focused mrnAs and 
neurological mirnAs 
The combined network analysis showed that the 
mRNA and particular miRNA data built a network with 
the deregulated unmodified and modified proteins (SI 
Figure S2 and S3). Changes in molecules associated with 
the extracellular space, plasma membrane, cytoplasm and 
nucleus were involved in all the brain regions in the APP/
PS1 mouse (SI Figure S2 and S3). The top three functions 
of these networks were in particular associated with 
cellular morphology and cell-cell signalling (Figure 8) in 
all the four brain regions that suggest neurodegeneration 
and a manifestation of altered synaptic plasticity.
Figure 5: Immunoblotting of total proteins with phospho-motifs against PKA, PKC and 14-3-3. Panel A to C show the 
fold-changes of proteins with phospho-motifs against PKA, PKC and 14-3-3, respectively. The columns represent the fold-changes with 
standard errors of the mean (SEM); n = 3; *p < 0.05; **p < 0.01; ***p < 0.001 (unpaired Student´s t-test). Normalization was performed 
against total lane intensity via Ponceau S staining. Panel D shows representative images of the immunoblotting following panel A-C with 
corresponding Ponceau S stainings. C, neocortex; BS, brainstem; H, hippocampus; OB, olfactory bulb; WT, wild-type.
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dIscussIon
APP/Ps1 mutation affects synaptic stathmin-
mediated cytoskeletal dynamics 
The aberrant phosphorylation of stathmin1 in one 
or more of its four serine residues (Ser16, Ser25, Ser38 
and Ser63) reduces its microtubule instability activity 
[16] with Ser16 and Ser63 as the main contributors 
[17]. These phospho-sites were affected in our phospho-
proteomics approach and are congruent with ELISA data 
of phospho-stathmin (Ser16). Interestingly, a reduced 
stathmin1 expression has been noted in the frontal and 
temporal neocortex of AD and Down syndrome patients 
[18]. Because stathmin1 functions as a key regulator 
of microtubule dynamics in dendrites [19], we suggest 
that the APP/PS1 mutations induce changes in dendritic 
Figure 6:Immunostaining of argyrophilic tau protein, Aß plaques and microglia clusters and specificity of Gallyas 
staining using human post-mortem brain samples. 20 µm-thick sagittal sections from transgenic and wild-type animals were 
stained for argyrophilic tau (A; Gallyas silver stain), Aβ (B; 6E10), and microglial cells (C; Anti-iba1). A. Gallyas-positive lesions were 
observed throughout the neocortex, in the olfactory bulb and hippocampus, but not the brainstem of transgenic APP/PS1 mice. The inserts 
show representative magnifications of cortical argyrophilic lesions, observed either isolated (left insert) or within a brown background 
(right insert). B. Aβ levels were high in the neocortex and the hippocampus of APP/PS1 mice. 6E10 immunoreactivity was observed in the 
olfactory bulb, but not the brainstem of transgenic animals. C. Arrows point to clusters of microglia in the olfactory bulb, neocortex, and 
the hippocampus of APP/PS1 mice. Scale bars: 100 µm (olfactory bulb, hippocampus, and brainstem); 200 µm (neocortex). GrO, granular 
cell layer of the olfactory bulb; EPI, external plexiform layer of the olfactory bulb; M2, secondary motor neocortex; VO, ventral orbital 
neocortex; CA1, field CA1 of hippocampus; DG, dentate gyrus; CA3, field CA3 of hippocampus; MVe, medial vestibular nucleus; Gi, 
gigantocellular reticular nucleus. Data represent from 3-4 biological replicates. D. To confirm the specificity of the Gallyas staining for 
abnormal tau in APP/PS1 mice, snap-frozen autopsy specimens from the neocortex of an AD patient and an aged-matched control were 
sectioned at 20 μm, and stained in parallel with mouse tissue. Argyrophilic neuropil threads (white arrows) were not observed in APP/PS1 
mice. Scale bar: 10 μm.E. Representative images of isotype controls.. All controls were diluted to the same protein concentration as the 
primary antibodies, and all sections were processed in parallel. Scale bar: 100 μm.
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microtubule cytoskeletal processing and dendrite 
arborisation, particularly in the neocortex and olfactory 
bulb. A dysregulated stathmin1 signalling, as indicated in 
the proteome analysis, cannot be ruled out in the APP/PS1 
hippocampus. This is also highlighted by alterations in the 
phosphorylation level of certain septins in the olfactory 
bulb (Sept4, Sept6) and microtubule-associated proteins 
(Map´s) in all four brain regions. Septins are critical for 
spine morphogenesis and dendrite development [20]. 
Additionally, we observed a number of cytoskeletal 
neurofilament proteins altered in their phosphorylation 
pattern (olfactory bulb: Nefh; brainstem: Nefh, Nefm; 
cortex: Nefl). 
We also showed changes in the sialylated N-linked 
glycosylation and phosphorylation pattern of neural / 
neuronal cell adhesion molecules (Ncam1, -2 and Nrcam) 
in all four APP/PS1 brain regions. They regulate neurite 
outgrowth and synapse modulation [21]. Notably, Aß 
affects synapse loss in AD hippocampus by disruption of 
Ncam2 [22] and overexpression of wild-type PS1 or PS1 
with a familial AD mutation (M146L) leads to decreased 
sialylation of Ncam in the neuroblastoma cell line SH-
SY5Y [23]. Recently, Hondius et al. demonstrated that 
the human post-mortem AD hippocampus has an altered 
expression of a number of proteins associated with 
extracellular matrix components and calcium-dependent 
signalling proteins that are linked to early changes in 
cytoskeletal dynamics and synaptic plasticity over the 
different Braak stages compared to matched controls [24]. 
Generally, changes in spine shape, -size and number 
depend on local cytoskeletal dynamics and signalling with 
synaptic activity being one of the most important factors 
that regulate Aβ levels [6]. 
Importantly, the regulation of Aβ levels also occurs 
at epigenetic level. It has been shown that miR101 
overexpression significantly reduces App and Aβ load 
Figure 7: Analysis of neurological miRNAs in the brain regions. Venn diagram showing the number of all and shared deregulated 
miRNAs in the hippocampus, olfactory bulb, neocortex and brainstem in 12 month old APP/PS1 male mice A.; n = 3. The number above 
each brain region shows the total number of significantly changed miRNAs per brain region. Panel B shows each significant deregulated 
miRNA with its fold-change per brain region. Panel C shows the significantly deregulated miRNAs (red box: up-regulated; no box: down-
regulated) per brain region associated to signalling pathways in a heat map presentation. 
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in hippocampal neurons [25]. Interestingly, a microRNA 
responsive element for miR101 was identified in the 
3’-untranslated region (UTR) of App [25]. We noted 
an increase in miR101-3p in the brainstem that may be 
sufficient to prevent Aβ plaques in the brain. Further, 
overexpression of miR106b negatively regulates the 
expression of endogenous App in cell lines targeting 
APP directly [26]. Our data indicate an upregulation of 
miR106b only in the hippocampus acting as a presumptive 
adaptive response to balance the increased App protein 
levels in our transgenic mouse model. However, some 
studies have also related miR106b to apoptosis in AD [27], 
but we exclude its role in apoptosis based on unchanged 
activated caspase-3 data in our study.
APP/PS1 mutations induce neurofibrillary tangle-
like structures
We demonstrated that NFT-like structures 
are apparent in 12 months old APP/PS1 mice in the 
neocortex, hippocampus and olfactory bulb but not in the 
brainstem. The argyrophilic structures were associated 
with a deregulated phosphorylation-pattern of tau protein 
(Mapt). Despite the scarcity of information regarding tau-
related pathology in APPswe/PS1ΔE9 mice, the aberrant 
phosphorylation of tau in this mouse model has been 
reported previously. For instance, phospho-tau has been 
observed in 6 and 9 months old APP/PS1 mice using 
immunohistochemistry with phospho-specific antibodies, 
targeting tau residues S199, S202, S262 and T191 [28]. 
In addition, assessment of tau hyperphosphorylation 
by immunoblotting in 3-7 months old APP/PS1 mice 
indicates that tau PMTs appear shortly after plaque 
deposition in this mouse model, and increase robustly with 
age [29] [30]. As age is an important contributing factor 
to neurodegeneration in general and AD in particular, 
we speculate that the early phosphorylation of Mapt in 
APPswe/PS1ΔE9 mice may underline the appearance 
of the Gallyas-positive argyrophilic structures observed 
here at 12 months of age. Thus, our study does not only 
confirm previous reports on the phosphorylation of ‘wild-
type’ tau in the APPswe/PS1ΔE9 mouse model, but also 
extends these observations to the proteomics level in four 
different brain regions, inviting further consideration of 
the mechanisms linking amyloidosis and tau aggregation 
Figure 8: Network integration of miRNA, mRNA and proteome data. The figure shows the top three biological/molecular 
functions of the networks in the hippocampus, olfactory bulb, neocortex and brainstem with the IPA scores.
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in animal models of AD, as previously discussed [31].
The present data implicate several microtubule-
regulating proteins in generating the argyrophilic 
structures in APPswe/PS1ΔE9 mice. Stathmin, for 
instance, was deregulated in APP/PS1 mice in several 
brain regions, most notably the neocortex and olfactory 
bulb, Of note, co-expression of stathmin with tau protein 
in COS-7 cells leads to microtubuli disruption and 
subsequent tau protein phosphorylation [32]. In addition, 
proteins such as 14-3-3, which play an important role in 
the abnormal fibrillization of tau in the AD brain [33], 
interacting with protein kinases and tau to facilitate its 
phosphorylation [34], were shown here to be deregulated 
in a region-specific manner. This suggests that an aberrant 
expression level and/or activity of 14-3-3 proteins in the 
olfactory bulb of both AD patients and APP/PS1 mice 
may link to NFT-like structures. In agreement with this 
study, Zelaya et al. noted a decrease in 14-3-3 proteins in 
the olfactory bulb of human post-mortem AD cases using 
proteomics [35]. They found an impressing number of 
deregulated proteins (231) that are involved in dendritic 
morphogenesis, neuronal injury and axonic distribution. 
The targets of this human study correlate well with our 
murine results. 
Although olfactory dysfunctions are evident in 
neurodegenerative diseases such as AD (90% in all cases) 
[36], few studies have examined this area using high 
throughput molecular approaches such as proteomics; 
data on the phosphorylation and N-linked sialylated 
glycosylation of proteins are even more underrepresented. 
Thus, our integrative approach and molecular data 
particularly in the olfactory bulb will support the 
identification of potential AD biomarkers.  
Figure 9: CREB-mediated signalling pathway. The figure shows the simplified CREB signalling pathway in neurons. Activated 
neuronal receptors (Growth factor-, Glutamate- and GPC receptors) intracellularly signal to kinase proteins (Ras/Raf, PKC, cAMK´s) 
phosphorylating MAPK proteins. This leads to phosphorylation of the transcription factor CREB shuttling to the nucleus and leads to 
transcription of genes that regulate synaptic plasticity. The signalling pathway can be regulated by miRNAs, Ppp´s and inflammatory 
cytokines such as TNFα triggered by oxidative stress, Aβ plaques / NF tangles or neuroinflammation. Ppp´s, protein phosphatases; GPC, 
G-protein coupled; NF, neurofilament.
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APP/PS1 mutation leads to a brain-region specific 
response in creb-mediated synaptic signalling 
and neuroinflammation 
The activation of CREB-mediated signalling 
pathways is necessary for the formation of synaptic long-
term memory [37, 38] controlling microtubule dynamics 
[39]. In detail, the protein kinases cAMK´s, PKA, PKC 
and MAPK, as well as several protein phosphatases 
(Ppp´s) regulate CREB activity by phosphorylation 
[40] (Figure 9). We noted a reduced phosphorylation 
of CREB at the main regulatory phospho-site (Ser133) 
only in the neocortex and olfactory bulb. An impaired 
CREB phosphorylation has been described in murine AD 
model [41] and human AD patients [42]. Our proteomic 
data indicated a deregulation on the phosphorylation 
level of the upstream kinases of CREB in the neocortex 
(downregulation of Camk2b, Prkcg, Mapk1; upregulation 
of Ppp3cb) and olfactory bulb (downregulation of 
Camk2b, Prkcb, Prkce and Ppp1cb). We demonstrated an 
increase in MAPK signalling and a suggested increased 
PKA- but unchanged PKC-signalling activity in the 
neocortex but not in the olfactory bulb, although we 
found a reduced phosphorylation status of Prkc´s using 
proteomics. The olfactory bulb-related alterations in these 
pathway axes culminating in CREB may be explained 
by expression changes of neuronal receptors on mRNA, 
protein and PTM level for growth factors (olfactory 
bulb: decreased Grb2, glyco-Lrp1; increased p-Gpr37l1; 
neocortex: increased glyco-Lrp1) and glutamate (olfactory 
bulb: decreased p-Grin1, Grin1, Grm7; neocortex: 
p-Grm2, glyco-Grin1, Grm8). 
We conclude from this data, that the APP/PS1 
mutation may lead to a reduced phosphorylation of 
cortical CREB that seems not to be balanced by induction 
of upstream regulation. The molecular mechanism of 
p-CREB reduction in the olfactory bulb may include 
changes in the neuronal receptor profile, Camk2b 
expression and protein phosphatase processing. The 
hippocampus seems to be unaffected regarding CREB 
signalling congruent with signalling pathway analysis 
of proteomics data. Interestingly, p-CREB levels 
seem to be unchanged in the brainstem, although we 
found a reduction in the cAMP metabolite. Notably, 
cAMP controls APP metabolism and Aß production as 
previously shown in neuronal cells [43]. Proteomics 
showed a number of phosphorylation changes in protein 
phosphatases in the brainstem (upregulation of Ppp3cb 
and Ppp3ca), protein kinases (upregulation of Prkcb and 
Prkar2b; downregulation of Prkce) and downregulation of 
Mapk3. Using immunoblotting, we found that PKC but 
not PKA signalling is inhibited in the brainstem by APP/
PS1 mutation. Moreover, we noted an upregulation of 
MAPK signalling (p-Erk1/2). It is known that the MAPK 
cascade involves both PKA and PKC signalling to CREB 
phosphorylation in the brain [44] (Figure 9). Thus, these 
results are congruent with IPA signalling pathway data. 
There are a number of evidences that an elevated 
MAPK activation is involved in early stages of AD [45]. 
Importantly, the activation of MAPK signalling occurs 
via cellular stress arising from inflammatory cytokines 
such as TNFα [46] or Aβ plaques [47]. We showed that 
elevated phosphorylation of Erk1/2 in the neocortex and 
brainstem is associated with Aβ plaques and increased 
TNFα expression, respectively, as well as increased 
apoptosis-inducing caspase3 levels in the brainstem. 
In contrast, we demonstrated that neuroinflammation 
(microglial clusters positive for iba1) exists in all 
analyzed brain regions except brainstem. As we used 
total brain region homogenates for TNFα and caspase3 
quantification, we cannot target these factors to a specific 
cell type. However, microglia seem to be their main source 
in other neurological conditions in mice [48] and in 12 
month old APP/PS1 mice [12]. Interestingly, in the APP/
PS1 mouse, TNFα was shown mainly to be expressed in 
those microglia, that had not taken up Aβ [12]. We also 
found increased neurotrophic Igf1 levels in the transgenic 
neocortex and hippocampus. Igf1 plays a trophic role in 
tissue injury with microglia being an important source of it 
[49]. Interestingly, a link between inflammation, neuronal 
dysfunction and defective insulin signalling has been 
demonstrated in AD [50] whereas Igf1 has also a major 
role in dendritic outgrowth [51]. Recent work to elucidate 
neuroinflammatory signals in APP/PS1 mice and AD in 
human beings emphasizes that the inflammatory changes 
in APP/PS1 mice coincided with Aβ deposition [52] [12]. 
Moreover, it was shown that major changes in the mRNA 
expression of immune response mediators, including 
cytokines, in the brain of wildtype mice occurred with 
ageing, which in humans is coincidental with the first 
alterations of sporadic AD-related pathology [52]. 
Regarding miRNA, miR146a regulates 
neuroinflammation [53]. A number of evidences point 
to its increased expression in APP/PS1 transgenic mice, 
such as in the neocortex of 6 month-old mice [54] and in 
the hippocampus and neocortex of AD patients [55, 56]. 
The increased expression of miR146 in the hippocampus 
(miR146a-5p) and neocortex (miR146b-5p) correlates 
with the presence of clusters of iba1-positive microglia 
in these brain regions. It is unclear whether miR-146 is an 
inhibitor of immune response and might be protective in 
neurodegenerative diseases [57].
Overall, we conclude that the olfactory bulb, 
neocortex, brainstem and hippocampus have a distinctively 
different molecular signature in male APPswe/PS1ΔE9 
mice, which might explain their differential sensitivity to 
AD-related pathology. It remains to be seen whether these 
changes correspond to post-mortem brains of human AD 
patients.   
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MAterIAls And Methods
ethics statement and tissue collection
Mouse brain tissue. Experiments were performed 
according to protocol number J.nr. 2011/561-1950 
approved by the Danish Animal Ethics Inspectorate. 
Male APP/PS1 (B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/
Mmjax) line 85 mice [58] and littermate wild-type mice 
were bred in the Biomedical Laboratory, University of 
Southern Denmark under a 12:12h light:dark cycle (lights 
on 6:30 am). Food and water were available ad libitum. 
Genotyping was performed in-house. Mice were sacrificed 
by cervical dislocation at the age of 12 months. Brains 
were excised and the left hemisphere was dissected for 
olfactory bulb, hippocampus, neocortex and the brainstem. 
The brain regions were immediately heat stabilized using 
the StabilizorTM T1 (Denator). The right hemisphere 
was snap-frozen in isopentane on dry-ice for staining 
experiments (-30°C). All brain samples were stored at 
-80°C until further processing. In total, 6 mice were used 
(3 mice per group).
Human brain tissue. As control for staining 
experiments on the mouse brain tissue, we used samples 
of frontal neocortex from AD patients (BB08-002) and a 
control case (BB07-015). The human brains were obtained 
from The Maritime Brain Tissue Bank, Department of 
Medical Neuroscience, Faculty of Medicine, Dalhousie 
University, Sir Charles Tupper Building, 5850 College 
Street, Halifax Nova Scotia B3H 1X5 following 
approval from the Danish Biomedical Research Ethical 
committee for the Region of Southern Denmark (Project 
Id. S-20070047) and the Nova Scotia Health Authority 
Research Ethics Board in Halifax, Canada. Informed, 
written consent forms were obtained from both donors. 
Brains were removed ≤24 hours post-mortem and frozen 
at -80°C. 
Isolation of total protein and rnA
The PARISTM kit (Ambion) was used to isolate 
proteins and total RNA from the same sample. Tissue 
samples were homogenised in manufacturer´s Cell 
Disruption Buffer including protease and phosphatase 
inhibitors (cOmplete Protease Inhibitor and PhosSTOP, 
Roche Diagnostics) on ice using a manual plastic 
mortar. An aliquot of the homogenate was saved for 
proteomics experiments (mass spectrometry, ELISA and 
immunoblotting) and stored at -20°C. The other part 
of the homogenate was processed for RNA isolation 
using manufacturer´s instructions and purified by 
RNeasy MinElute Cleanup Kit (Qiagen); RNA was 
eluted in nuclease-free water. The optical density 
(OD) ratio of 260/280 was measured using a Nanodrop 
spectrophotometer (PeqLab Biotechnology); it ranged 
between 1.9 and 2.0. RNA samples were stored at -20°C.
Mass spectrometry-based proteomics 
The complete sample processing workflow is 
depicted in Figure 1 A. Figure 1 B shows the number 
of identifications and quantifications of the proteomics 
experiments.
reduction, alkylation and enzymatic digestion
150 µg total proteins were denatured and reduced 
in 6 M urea, 2 M thiourea, 10 mM DTT, 20 mM TEAB, 
pH 7.5 at room temperature (RT). After vortexing 
and sonication, proteins were alkylated in 20 mM 
iodoacetamide (IAA) for 20 minutes in the dark. A total of 
2 µl of endoproteinase Lys-C (6 µg/µl, Wako) was added 
to the protein sample and the solution was incubated for 
2 hours at RT. The sample was diluted 10 times with 
20 mM TEAB, pH 7.5 and digested with trypsin (1:50 
(w/w) trypsin:protein) overnight at 37°C. The enzymatic 
digestion was stopped with 5% formic acid (FA) and the 
peptide sample was cleared by centrifugation (14000 x 
g, 15 minutes). Protein and peptide quantification was 
performed by fluorometric quantification (QubitTM – Life 
technologies). 
ItrAQ labelling
A total of 75 µg tryptic peptides per brain region and 
condition were dried and desalted with R2/R3 columns 
(as described under Sample desalting with R2/R3 micro-
column) before iTRAQ-8plex labelling (AB Sciex). 
Labelling was performed as follows: iTRAQ-113 for 
hippocampus wild-type, iTRAQ-114 for hippocampus AD 
mouse, iTRAQ-115 for neocortex wild-type, iTRAQ-116 
for neocortex AD mouse, iTRAQ-117 for olfactory bulb 
wild-type, iTRAQ-118 for olfactory bulb AD mouse, 
iTRAQ-119 for brainstem wild-type and iTRAQ-121 
for brainstem AD mouse. Three biological replicates 
were used. The labelling was performed according to 
manufacturer´s instruction. The labelled peptides of each 
wild-type and mutated hippocampus, neocortex, olfactory 
bulb and brainstem were mixed 1:1:1:1:1:1:1:1, dried 
down and stored for further enrichment and analysis.
enrichment of phospho-peptides and formerly 
sialylated n-linked glycopeptides (deglycosylated)
Multi- and monophosphorylated peptides as well 
as sialylated N-linked glycopeptides were separated from 
unmodified peptides using a TiO2-SIMAC-TiO2 (TiSH) 
workflow: Modified peptides bind to TiO2 beads because 
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the phospho and sialic groups are acid and hence retained 
in the column, whereas unmodified peptides flow-through; 
following SIMAC (sequential elution from IMAC beads) 
[59], multiphosphorylated peptides are enriched and 
eluted separately from the monophosphorylated and 
deglycopeptides that are, in turn, separated in a second 
TiO2 step [60-63] (Figure 1 A). The eluted modified 
peptides from the first TiO2 step were deglycosylated to 
remove N-linked glycans [61]. Hydrophilic interaction 
chromatography (HILIC) was used as sample fractionation 
prior to nano liquid chromatography-tandem mass 
spectrometry (LC-MS/MS).  
Briefly, the combined labelled peptides were 
dissolved in TiO2 loading buffer (80% acetonitrile (ACN), 
5% trifluoroacetic acid (TFA) and 1 M glycolic acid) and 
incubated with 3.6 mg of TiO2 (5020 titansphere TiO2, 
5µm; a kind gift from GL Sciences, Japan) beads for 
30 minutes at RT. The beads were sequentially washed 
with TiO2 loading buffer, 80% ACN/1% TFA and 10% 
ACN/0.1% TFA. Modified peptides were eluted with 
1.5% ammonium hydroxide solution, pH 11.3, and dried. 
The unbound TiO2 fraction and the combined washing 
fractions contain unmodified peptides. The dried modified 
peptides were deglycosylated in 20 mM TEAB, pH 8.0 
with N-glycosidase F (P0705L, Biolabs) and Sialidase 
A (GK80046, Prozyme) at 37°C overnight. The sample 
was dried and resuspended in SIMAC loading buffer 
(50 % ACN, 0.1% TFA) and incubated with PhosSelect 
IMAC beads (P9740, Sigma) pre-equilibrated in SIMAC 
loading buffer. After 30 minutes under gentle shaking at 
RT, beads were washed in SIMAC loading buffer and 
monophosphorylated / deglycopeptides were eluted with 
20% ACN, 1% TFA and combined with the washing 
fraction (SIMAC FT) and dried; multiphosphorylated 
peptides were eluted with 1.5% ammonium hydroxide 
solution, pH 11.3, and dried down. The second TiO2 step 
was performed with the SIMAC FT and 1% TFA elution. 
All the eluates were dried and desalted on micro-columns 
before capillary HILIC fractionation.      
sample desalting with r2/r3 micro-column
The samples were desalted before HILIC 
fractionation using home-made P200-tip-based columns 
packed with equal ratios of Poros R2 (Oligo R2 Reversed 
Phase Resin 1-1112-46, Applied Biosystems) and Poros 
R3 (OligoR3 Reversed Phase Resin 1-1339-03, Applied 
Biosystems) reversed-phase resin material. The end of 
the tip was blocked with C8 material (Model 2314, 3m 
EmporeTM C8). The column was prepared by short 
centrifugation (1000xg) of the R3 reversed-phase resin 
(100% ACN). The column was equilibrated with 0.1% 
TFA and centrifuged again. The acidified samples were 
loaded onto the columns and washed / centrifuged three 
times with 0.1% TFA. Peptides were eluted with 60% 
ACN, 0.1% TFA and dried.    
hIlIc fractionation 
The fractions containing mono-phosphorylated, 
deglycosylated and unmodified peptides were fractionated 
prior to nano LC-MS/MS analysis using HILIC as 
described previously [63, 64]. Peptides were dissolved 
in 90% ACN, 0.1% TFA (solvent B) and loaded onto a 
450 μm OD x 320 μm ID x 17 cm micro-capillary column 
packed with TSK Amide-80 (3 μm; Tosoh Bioscience) 
using an Agilent 1200 Series HPLC (Agilent). The 
peptides were separated using a gradient from 100–60% 
solvent B (A = 0.1% TFA) in 30 min at a flow-rate of 
6 μl/min. Fractions were collected every 1 min based on 
the UV chromatogram. Subsequently, the peptide fractions 
were dried by vacuum centrifugation.
reversed-phase nanolc-esI-Ms/Ms 
The peptides (resuspended in 0.1% FA) were 
automatically injected and loaded on a ReproSil-Pur 
C18 AQ (Dr. Maisch, Ammerbuch-Entringen, Germany) 
in-house packed trap column (2 cm x 100 µm inner 
diameter; 5 µm). The peptides were separated at 250 
nl/min on an analytical ReproSil-Pur C18 AQ (Dr. 
Maisch, Ammerbuch-Entringen, Germany) packed in-
house column (17 cm x 75 µm; 3 µm) by reversed phase 
chromatography which was operated on an EASY-nanoLC 
system (Thermo Fisher Scientific, Odense, Denmark). 
Mobile phase was 95% ACN/ 0.1% FA (B) and water/0.1% 
FA (A). Depending on the samples, the gradient was from 
1% to 30% solvent B in 80 (mono-phosphoralyated-, 
deglycosylated- and unmodified peptides) or 110 min 
(multiphosphorylated peptides), 30 - 50% B in 10 min, 
50 - 100% B in 5 min and 8 min at 100% B. The nano-
LC was online connected to a Q Exactive HF Hybrid 
Quadrupole-Orbitrap mass spectrometer (Thermo Fisher 
Scientific) operating in positive ion mode and using data-
dependent acquisition. The Orbitrap acquired the full MS 
scan with an automatic gain control (AGC) target value 
of 3x106 ions and a maximum fill time of 100 ms. Each 
MS scan was acquired at high-resolution (120,000 full-
width half maximum (FWHM) at m/z 200 in the Orbitrap 
with a mass range of 400-1400 Da. The 12 most abundant 
peptide ions were selected from the MS for higher energy 
collision-induced dissociation (HCD) fragmentation 
(collision energy: 34 V) if they were at least doubly 
charged. Fragmentation was performed at high resolution 
(60,000 FWHM) for a target of 1x105 and a maximum 
injection time of 60 ms using an isolation window of 1.2 
m/z and a dynamic exclusion of 20 s. 
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data analysis 
Raw data were searched against the Swissprot 
database and Uniprot mouse reference database via 
Mascot (v2.3.02, Matrix Science) and Sequest HT 
search engines, respectively, using Proteome Discoverer 
(v1.4.1.14, Thermo Fisher Scientific). A precursor mass 
tolerance of 10 ppm and a product ion mass tolerance 
of 0.02 Da were applied allowing not more than one 
missed cleavage for trypsin. Fixed modifications included 
carbamidomethylation of Cys and iTRAQ8-plex labeling 
for Lys and N-terminal. Variable modifications contained 
phosphorylation on Ser/Thr/Tyr and deamidation of Asn. 
The iTRAQ datasets were quantified using the centroid 
peak intensity with the “reporter ions quantfier” node. 
To ensure a high-confident identification of peptides, 
we used the Mascot percolator algorithm (q value filter 
set to 0.01), Mascot and Sequest HT peptide rank 1 and 
a cut-off value of Mascot score ≥ 22 as well as Sequest 
HT ΔCn of 0.1. Moreover, a cut-off value of Xcorr score 
for charge states of +1, +2, +3 and +4 higher than 1.5, 
2, 2.25 and 2.5, respectively, were considered for further 
analysis. Subsequently, these peptides were filtered against 
a Decoy database resulting into a false discovery rate 
(FDR) to 0.01 (FDR < 0.01). Three biological replicates 
were considered for the statistical analysis. Quantification 
was performed on the log2-values of the measured 
peptide intensities and the data were normalized based 
on the median. Modified peptides were merged with the 
R Rollup function (http://omics.pnl.gov/software/danter) 
allowing for one-hit-wonders and using the mean of the 
normalized intensities for each peptide. Quantification of 
proteins was obtained by merging the unmodified peptides 
with the R Rollup function considering at least 2 unique 
peptides not allowing for one-hit-wonders and using the 
mean of the intensities. Subsequently, the mean over the 
experimental conditions for each peptide in each replicate 
was subtracted in order to merge the data from different 
replicates. Proteins with proteoforms were deleted during 
data analysis. Principal component analyses (PCA) were 
performed to assess sample quality when comparing 
the different experimental conditions (individual brain 
region between wild-type and APP/PS1 mice). Proteins, 
phosphopeptides (localized by phosphoRS node 
within the Proteome Discoverer software)and formerly 
sialylated N-linked glycopeptides with a consensus 
motif for N-linked glycosylation (NXS/T/C; where X 
# P) were considered to be significantly deregulated if 
they fulfilled the following criteria: (1) identification by 
at least two unique peptides (proteins) or at least one 
unique peptide (post-translationally modified peptides) 
in n-1 replicates (n: number of biological replicates), (2) 
quantification with a standard deviation (SD) of ≤ 30% 
between the replicates and a ratio of ≥ 1.30 or ≤ 0.77. 
The threshold for the ratio was calculated on the average 
experimental technical variance of the multiple analyses 
of brain technical replicates in mass spectrometry analysis 
[65]. Phosphorylated and deglycosylated peptides were 
normalized based on the protein expression in each of 
the replicates including the proteins with only one unique 
peptide to ensure that deregulation occurred on PTM level 
and not on protein level.  
The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium [66] via 
the PRIDE partner repository with the dataset identifier 
PXD003312 (username: reviewer10739@ebi.ac.uk; 
password: Fztk4CaX)
Quantification of mRNA and miRNA via 
quantitative PCR
A total of 100 ng of RNA isolates were used to 
quantify miRNA expression (miScript miRNA PCR 
Array “Neurological Development & Disease” [MIMM-
107Z – Qiagen]) and gene expression (RT2 Profiler PCR 
Array “Synaptic Plasticity” [PAMM-126Z – Qiagen]) 
levels according to the manufacturer´s protocol on a 
StepOnePlus device (Applied Biosystems). Expression 
levels of miRNAs and mRNAs were calculated based on 
the 2-ΔΔCt method with normalisation against the median of 
all target miRNAs / mRNAs, respectively. Changes were 
considered significant if they reached a p-value of ≤ 0.05 
(unpaired Student´s t-test, two-sided, n=3) and had a fold-
change of ≥ 1.2 or ≤ -1.2. The threshold of ±1.2 is based 
on the previous average experimental technical variance 
of 8.4% of a set of 14 overlapping targets gained in the 
neocortex and hippocampus [65]. Thus, a threshold of 
±1.2 enables confident target identification [67]. 
bioinformatics analysis of protein classes, 
phospho-sites and affected signalling pathways
Deregulated proteins were categorised into protein 
classes using PANTHER (Protein Analysis Through 
Evolutionary Relationships) classification system software 
(http://www.pantherdb.org) and the general annotation 
from UniProt (http://uniprot.org). Gene ontology (GO) 
analysis of biological processes and cellular components 
was performed with STRING software (http://string-db.
org). The analyses of affected signalling pathways from 
all deregulated proteins and posttranslational modified 
(PTM) proteins were performed with the INGENUITY 
Pathway Analysis (http://www.ingenuity.com) software 
tool that comprises curated information from databases of 
experimental and predictive origin, enabling discovery of 
highly represented functions and pathways. The mean of 
the ratios of all deregulated PTM-peptides per protein was 
used for signalling pathway analysis. Network analysis 
was performed by uploading the deregulated unmodified 
proteins, phospho-proteins and glyco-proteins as well 
as miRNA and mRNA expression data. We used only 
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the database information of experimental and predictive 
origin regarding central nervous system to be confident 
about the potential affected signalling pathways. The IPA 
comparison analysis takes into account the signalling 
pathway rank according to the calculated p-value 
and reports it hierarchically. The software generates 
significance values (p-values) between each biological or 
molecular event and the imported proteins based on the 
Fisher´s exact test (p ≤ 0.05). 
MiRNA data were analysed with DIANA miRPath 
v.2.0 software [68] and the signalling pathways were 
visualised in a heatmap presentation by applying a p-value 
threshold of ≤ 0.05 (Fisher´s meta-analysis) and FDR 
correction (Benjamini & Hochberg).
Phospho-sites related to Alzheimer's were manually 
compared with known information from PhosphoSitePlus 
database (http://www.phosphosite.org).
enzyme-linked immunosorbent assay (elIsA) 
A total of 5 µg of protein lysates were used 
to quantify total CREB (KHO0231, Invitrogen), 
p-CREB (Ser133) (KHO0241, Invitrogen), Stathmin1 
(E03S0217, Bluegene), Caspase3 (SEA626Mu, Cloud-
Clone Corp.), cAMP (KGE012B, R&D Systems) and 
TNFα (BMS607HS, eBioscience) using enzyme-linked 
immunosorbent assay (ELISA) after manufacturer´s 
instructions. P-Stathmin1 (Ser16) was quantified by 
using the Stathmin1 ELISA (E03S0217, Bluegene) and 
primary antibody against p-Stathmin1 (Ser16) (ab47328, 
Abcam) and secondary detector antibody (anti-rabbit IgG, 
HRP-linked) (#7074, Cell Signalling). The plates were 
measured on a FLUOstar Omega (BMG Labtech) at the 
recommended wavelength of the manufacturer. All assays 
were normalised against GAPDH (ab176642, Abcam) as 
it was not changed in the proteomics and transcriptomics 
data. Three biological replicates from hippocampus, 
neocortex, olfactory bulb and brainstem were analyzed 
in duplicates. The mean of each technical triplicate was 
normalised against the mean of the representative GAPDH 
technical replicates. Statistical analysis between APP/
PS1 and age-matched wild-type mice was performed via 
unpaired Student´s t-test and data are presented as fold-
changes with the standard error of the mean (SEM).  
light microscopy 
Fresh-frozen, 20 µm-thick sections were used in 
all staining experiments (mouse brain and human brain 
tissue). Adjacent serial sections were collected at 300 
µm intervals in a Leica CM3050S cryostat (Nussloch, 
Germany), at -17ºC. The sections were mounted onto 
SuperfrostTM Plus microscope slides, stored at -80ºC, and 
processed within 1 month of collection.
For the Gallyas silver stain, sections were initially 
thaw-fixed in 4% Neutral Buffered Formalin (NBF) at 
4ºC for 24 h. The sections were subsequently washed 
in distilled water (5 x 2 min) and defatted for 1 h in a 
solution of chloroform/99% ethanol (1:1). Following 
hydration through a series of graded ethanol into distilled 
water (2 x 1 min: 99%, 96%, 70%), sections were stained 
for neurofibrillary tangles according to the Kuninaka et 
al. 2015 modification [69] of the Gallyas method [70]. 
Briefly, slides were immersed into an aqueous solution 
of 0.25% potassium permanganate (20 min), washed in 
distilled water (1min), and incubated in 1% oxalic acid (2 
min). After washing in distilled water (2 x 5 min), sections 
were transferred into an alkaline silver iodide solution 
(1 min), washed with 0.5% acetic acid (2 x 5 min), and 
developed until the appearance of a brownish shade (~10 
min). The stained sections were then washed in 0.5% 
acetic acid (3 min), toned with 0.1% gold chloride (10 
min), and fixed with 1% sodium thiosulfate (5 min). 
Aβ immunohistochemistry was performed using 
the biotinylated 6E10 mouse anti-human antibody (SIG-
39340; NordicBiosite, Norway), as detailed previously 
[12]. NBF post-fixed sections were treated with 70% FA 
(30 min), permeabilised in 50 mM Tris-buffered saline 
(TBS) containing 1% Triton X-100 (TBSTx; 3 x 15 
min), and blocked in TBSTx containing 10% fetal bovine 
serum (FBS, 30 min). The primary antibody was diluted 
in TBS+10% FBS buffer and applied overnight at 4ºC 
(1:500 dilution of stock). The sections were subsequently 
brought to RT, washed in TBSTx (3 x 15 min), and 
quenched for endogenous peroxidase activity in a solution 
of TBS/methanol/30% water (8:1:1; 20 min). After 
washing in TBSTx (3 x 15 min), sections were incubated 
with streptavidin-conjugated horseradish peroxidase for 
3 h (SA-HRP, GE Healthcare, UK). Following 3 x 10 
min washes in TBS, peroxidase activity was visualised 
with 0.05% 3,3′diaminobenzidine (DAB) in TBS buffer, 
containing 0.01% H2O2.
Microglial cells were stained using the rabbit 
polyclonal anti-Iba1 antibody (WAKO Chemicals GmbH, 
Germany). Sections were fixed in 4% paraformaldehyde 
(PFA) [71] for 24 h at 4ºC, followed by fixation in 1% 
PFA at RT for an additional 24 h. After 5 x 2 min washes 
in TBS, sections were defatted for 1 h in a solution of 
chloroform/99% ethanol (1:1), and hydrated through 
graded alcohol into TBS (2 x 1 min: 99%, 96%, 70%). 
Endogenous peroxidase activity was quenched using 1.5% 
H2O2 in TBS (30 min). Sections were subsequently washed 
and treated for 30 min with 0.25% sodium borohydride, to 
reduce unreactive aldehydes and Schiff bases. Following 
thorough washing in TBS, the sections were immersed 
in TBS+0.5% Triton X-100 (4 x 15 min), and incubated 
with primary antibody in the same buffer for 48 h (1:5,000 
dilution of stock). After washing in TBS+0.5% Triton 
X-100 (4 x 15 min), the anti-rabbit EnVision+ HRP-
labelled polymer was applied to the sections for 3 h (Dako, 
Denmark). The stain was developed using 0.05% DAB, 10 
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mM imidazole and 0.5% nickel ammonium hexahydrate, 
according to a recently published procedure [72]. 
After each staining protocol, sections were washed 
in water, dehydrated in graded alcohols, cleared in 
xylene, and cover-slipped with PERTEX (HistoLab, 
Denmark). For immunohistochemistry, omission of 
primary antibodies, and the mouse biotin-labelled 
IgG1 (ThermoFisher Scientific, Denmark) or the rabbit 
immunoglobulin fraction (Dako, Denmark) were used 
to confirm the specificity of 6E10 and anti-Iba1 for Aβ 
peptides and microglia cells, respectively.
Quantification of proteins and phosphorylation-
motifs by immunoblotting
Protein extracts (15 µg) were separated on 4-12% 
Bolt Bis-Tris gradient gels (NW04125Box, Novex) and 
transferred to polyvinylidene fluoride (PVDF) membranes 
via the TransBlot SD Semi-Dry Transfer Cell Blotter 
system (Biorad). The protein content on the membranes 
was visualised with Ponceau S. The membranes were 
incubated in blocking buffer (5% milk) washed and 
incubated overnight at 4 °C with primary antibody 
dilutions as recommended by the manufacturer (Phospho-
PKC Substrate Motif (R/KXpSX(R/K) MultiMab Rabbit 
Monoclonal Antibody – #6967, Cell Signalling; Phospho-
(Ser) 14-3-3 Binding Motif Rabbit Antibody - #9601, 
Cell Signalling; Phospho-PKA Substrate (RRXS*/T*) 
(100G7E) Rabbit Monoclonal Antibody - #9624, Cell 
Signalling; rabbit polyclonal antibody against p44/42 
MAPK (Erk1/2) - #9102, Cell Signalling; rabbit polyclonal 
antibody against phospho-p44/p42 MAPK (Erk1/2) 
(Thr202/Tyr204) - #9101, Cell Signalling, goat polyclonal 
antibody against malondialdehyde (MDA) – ab20703, 
Abcam and goat polyclonal antibody against GAPDH – 
ab9483, Abcam. The blots were washed and incubated 
with horseradish peroxidase-conjugated secondary 
antibody (anti-rabbit IgG, HRP-linked antibody - #7074, 
Cell Signalling or anti-goat IgG, HRP-linked antibody – 
ab6741, Abcam) in 5% milk for 2 hours. Subsequently, 
blots were washed and developed with ECL system 
(LuminataTM Forte Western HRP Substrate, WBLUF0100, 
Millipore) using standard protocol from the manufacturer. 
Immunoblots were considered for quantification if (i) the 
pattern and intensity of lanes stained with PonceauS were 
equal and total lane intensity of the PonceauS-stained 
proteins was similar within the biological replicates. For 
phospho-motif and MDA immunoblots, the total lane 
intensity was selected as a representative indicator of 
global changes in PKA-, PKC-, 14-3-3-phospho motifs 
and oxidative stress, respectively. Immunoblots were 
quantified with TotalLab TL100 software (www.totallab.
com) using software-suggested background correction. 
Each band was normalised against the total lane intensity 
obtained by Ponceau S (phospho motif immunoblots and 
MDA blots) or against GAPDH (phospho Erk1/2 and 
Erk1/2) that was not changed during our transcriptomics 
and proteomics analysis. Fold-changes were calculated 
between APP/PS1 and wild-type mice from hippocampus, 
neocortex, olfactory bulb and brainstem separately. In case 
of ERK1/2 and p-ERK1/2 quantification, we quantified 
one lane corresponding to ERK1 and ERK2 as well as 
p-ERK1 and p-ERK2, respectively. Three biological 
replicates were used for statistical analysis (Student´s 
t-test, unpaired) with a significance threshold of 0.05.
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